From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3266 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Lisa Cuba und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Medication Errors, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Medikationssicherheit
Abstract (Originalsprache)
The randomized AMBORA trial showed that medication errors are frequent in patients treated with oral antitumor therapeutics and that they can be substantially reduced by an intensified clinical pharmacological/pharmaceutical care program. While randomized controlled trials are essential to generate clinical evidence, their generalizability in real‐world is not always given. The AMBORA care program was implemented in clinical routine within the AMBORA Competence and Consultation Center (AMBORA Center) at the Comprehensive Cancer Center Erlangen‐EMN, allowing a thorough comparison of medication error frequencies and characteristics. Our primary analysis compared data at therapy initiation of new oral antitumor therapeutics from the AMBORA trial intervention group ( n = 98) and the AMBORA Center ( n = 142). Medication errors involving the oral antitumor therapeutics were twofold higher in real‐world compared to the randomized controlled trial (mean 0.83 ± 0.80 per patient vs. 0.41 ± 0.53, P < 0.001). We observed more complex oral antitumor therapeutic regimens, a higher median number of medications, and a higher ECOG status in clinical routine vs. the randomized trial. A high percentage of medication errors was completely solved in both groups (85.7% vs. 88.3%, ns). Medication error characteristics within the complete medication (oral antitumor therapeutics and concomitant medication) were similar in both groups (e.g., patient‐related causes, drug–drug/drug–food interactions). Taken together, medication errors were even more frequent in clinical routine than in the randomized controlled trial and a high rate was solved in clinical routine by a clinical pharmacological/pharmaceutical care program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Pharmacy Department, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-EMN, Universitätsklinikum Erlangen, Erlangen, Germany.
- Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
- FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
ORCID-Profile: Lisa Cuba, Pauline Dürr, Frank Dörje, Martin F Fromm, Katja Schlichtig
Zitieren
APA
Cuba, L., Dürr, P., Dörje, F., Fromm, M. F., & Schlichtig, K. (2024). From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3266
Vancouver
Cuba L, Dürr P, Dörje F, Fromm MF, Schlichtig K. From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3266
BibTeX
@article{Cuba2024,
author = {Cuba, Lisa and Dürr, Pauline and Dörje, Frank and Fromm, Martin F and Schlichtig, Katja},
title = {From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3266}
}
EUVIMED